vimarsana.com

Latest Breaking News On - Group of patients - Page 1 : vimarsana.com

No Decline in Cognition Scores in Patients with Mild Alzheimer s Disease Who Received Simufilam Continuously For 24 Months

ADAS-Cog Scores Were Stable in a Group of Patients with Mild Alzheimer’s Who Received Drug Candidate Simufilam Continuously, Baseline to Month 24.Mild Alzheimer’s Patients Who Received Simufilam.

No Decline in Cognition Scores in Patients with Mild Alzheimer s Disease Who Received

ADAS-Cog Scores Were Stable in a Group of Patients with Mild Alzheimer’s Who Received Drug Candidate Simufilam Continuously, Baseline to Month 24. Mild Alzheimer’s Patients Who Received Simufilam Non-Continuously Declined a Group Average of 1 Point on ADAS-Cog, Baseline to Month 24. Oral Simufilam Safe, Well-Tolerated. AUSTIN, Texas, Feb. 07, 2024 (GLOBE NEWSWIRE) Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company, today reported top-line results of a two-year clinical safety

vimarsana © 2020. All Rights Reserved.